Cited 0 times in

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”

DC Field Value Language
dc.contributor.author김도영-
dc.date.accessioned2025-02-03T09:15:01Z-
dc.date.available2025-02-03T09:15:01Z-
dc.date.issued2024-10-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/202325-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleCorrespondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYoung Eun Chon-
dc.contributor.googleauthorDong Yun Kim-
dc.contributor.googleauthorHong Jae Chon-
dc.contributor.googleauthorDo Young Kim-
dc.identifier.doi10.3350/CMH.2024.0394-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid38816178-
dc.subject.keywordAtezolizumab and bevacizumab failure-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordImmune check point inhibitor-
dc.subject.keywordSalvage therapy-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.citation.volume30-
dc.citation.number4-
dc.citation.startPage1005-
dc.citation.endPage1008-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.30(4) : 1005-1008, 2024-10-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.